|Articles|November 22, 2017
HIV Drug Approval Highlights SPT Week in Review
Author(s)SPT Staff
Top news of the week from Specialty Pharmacy Times.
Advertisement
5. Cancer Immunotherapy Possible for HIV-Positive Patients
Many immunotherapy clinical trials exclude HIV-positive patients with cancer.
4. P
harmacy Times Continuing Education Participates in #APharmacistIs Campaign
The #APharmacistIs campaign demonstrates the value of pharmacists in improving the lives of patients.
3.
Medication Adherence: How Technology Can Help Solve This Billion Dollar Hurdle
Customized technology may help specialty pharmacies drive adherence and patient outcomes.
2. FDA Kicks Drug Approvals into Overdrive
The FDA granted approval to numerous specialty drugs last week.
1. First Complete Two-Drug HIV Regimen Receives FDA Approval
Juluca is indicated as a complete therapy for patients with HIV-1.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Regular Melatonin Supplementation May Hide Hidden Heart Complications
2
From Type 1 to Type 2 and Beyond: Navigating the Landscape of Diabetes
3
FDA Announces Recall 580,000 Bottles of Prazosin Over Potential Carcinogenic Impurity
4
COVID-19 Reinfection Heightens Risk of Postacute Sequelae of SARS-CoV-2 in Pediatrics
5
